Fourth Annual Chicago Supportive Oncology Conference

Community Oncology

Volume 2, Number 4 (July/August 2005)

Letter from the Editor

289

 

Proving the quality of our care

Lee S. Schwartzberg, MD, FACP, Editor-in-Chief

The West Clinic, Memphis, TN

The concept of quality oncology care isn’t new; we all aspire to and usually deliver it. What we haven’t done is prove the cost effectiveness of our cancer treatment to payers, patients, and even to ourselves. It’s time for oncologists to lead this discussion and direct the process, rather than have it handed to us by middlemen with their own agenda.

full text 40 kb

Original Research

293

 

Uncompensated costs associated with the outpatient management of cancer chemotherapy–associated febrile neutropenia

Elizabeth A. Calhoun, PhD, Sheila Brown, RN, BSN, MHSA, Mark S. Kozloff, MD, and Charles L. Bennett, MD, PhD, MPP

University of Illinois, Chicago, Northwestern University Medical School, Chicago, and Ingalls Hospital and Monroe Medical Associates, Harvey, IL

For a small community oncology practice, the costs of managing chemotherapy-related neutropenia can be considerable. The findings of this report raise concerns about Medicare reimbursement changes. The changes could lead to clinically important decrements in cancer care, possibly with poorer outcomes for patients.

abstract full text 86 kb

Community Translations

299

 

Defining targets and protecting normal tissues in inverse-planned IMRT for prostate, head and neck, and gynecologic cancers: a comparative review

Anthony E. Dragun, MD, Joseph F. Harmon, PhD, and Eric G. Aguero, MD

Hollings Cancer Center, Charleston, SC

The rise of interest in intensity-modulated radiation therapy has been astronomical. It’s no surprise: IMRT spares normal tissues surrounded by targets and allows for a higher tumor radiation dose. The resulting dose distributions are almost always superior to those achieved with traditional radiation planning approaches, particularly in patients with complex and concave targets.

abstract full text 178 kb

Community Dialogue

314

 

Are Americans ready for cancer prevention in a pill?

Community Oncology interviews Leslie Ford, MD, Associate Director for Clinical Research, Division of Cancer Prevention, National Cancer Institute, Bethesda, MD

Preventing cancer should be an easy sell. But for a variety of reasons, Americans have not yet embraced the concept, despite years of highly publicized research at NCI for ways to prevent breast, prostate, and colon cancers. It’s not like cardiology, where doctors treat a problem such as high blood pressure to reduce stroke risk. Patients accept that, but there’s no analog in oncology.

full text 82 kb

Controversies in Patient Management

331

 

Adjuvant therapy for colon cancer in the elderly: treat or don’t treat?

Jason S. Levitz, MD, and Stuart M. Lichtman, MD

North Shore University Hospital, Manhasset, and Memorial Sloan-Kettering Cancer Center at Suffolk, Commack, NY

Elderly patients receive the same benefits from adjuvant therapy as do younger patients—and have about the same level of risk.

abstract full text 124 kb

Challenging Cases/Rare Cancers

339

 

Occult systemic malignancy masquerading as thrombotic thrombocytopenic purpura–hemolytic uremic syndrome

Kristin K. Francis, MD, Kiarash Kojouri, MD, MPH, and James N. George, MD

The University of Oklahoma Health Sciences Center, Oklahoma City, OK

In retrospect, a bone marrow biopsy might have documented the presence of metastatic cancer in the patient whose case is reported here. But plasma exchange for TTP-HUS was initiated; it was the right treatment for the wrong disease.

abstract full text 127 kb

Quality Care

351

 

A call for action: leadership is needed now on quality, safety, and pay for performance in community oncology

Linda D. Bosserman, MD

Wilshire Medical Oncology Group, Inc., La Verne, CA

We have elevated the quality of cancer care in this country. But now we must communicate that success and more fully articulate its value. Because of changes in Medicare, the need to lead the quality care movement is urgent.

abstract full text 122 kb

Economics/Practice Management

357

 

The new language of cancer care: contribution to working capital, human resource costs, practice efficiency, and opportunity costs

Barry V. Fortner, PhD, Ling Zhu, MS, and Ted Okon, MBA

Baptist Centers for Cancer Care and Supportive Oncology Services, Inc., Memphis, TN

To stay economically viable, community oncology clinics must increase the efficiency of patient visits without compromising patient care.

abstract full text 152 kb

Practice Survival

318

 

Unmet expectations

Myron Goldsmith, MD

Huntington Beach, CA

All oncologists have seen patients undergo a crisis of faith. But it came as a shock when this patient–a priest–shook his fist at God.

full text 55 kb

Brief Communications

324

 

A case of breast cancer detected by a pet dog

James S. Welsh, MS, MD, Darryl Barton, MD, and Harish Ahuja, MD

UW Cancer Center/Wausau Hospital, Wausau WI

A dachshund puppy sniffed and poked at its owner’s left axilla. The dog’s diagnosis: infiltrating ductal carcinoma.

full text 68 kb

324

 

Hypersensitivity reaction to carboplatin followed by reaction to cisplatin

Daniel J. Morris, MD, and Barbara Carr, RN, OCN

Naples Community Hospital, Naples, FL

Although physicians have successfully administered cisplatin to carboplatin-allergic patients, these authors detail a case of hypersensitivity to both drugs.

full text 44 kb

Legal Matters

345

 

Ask your lawyer

Lee W. Doty, Esq.

Philadelphia, PA

A practice wants to take on a new doctor. How can it protect itself if things go sour?

full text 69 kb

Washington Update

365

 

President Bush asked to extend Medicare demonstration project

Ted Okon and Steve Coplon

Community Oncology Alliance, Memphis, TN

Politicians from both sides of the aisle are coming together on this issue.

full text 47 kb

366

 

Consequences of the Medicare Modernization Act

A report on the anxious discussion at the 10th annual NCCN conference.

full text 47 kb

© 2005 by Elsevier Inc. All rights reserved. No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopy, recording, or any information storage and retrieval system, without permission in writing from the publisher.

The opinions expressed herein are those of the authors or advertisers. The authors, editors, and publishers make every effort to ensure that no inaccurate or misleading data, opinion, or statement is published in this journal and that drug names, dosages, and recommendations are accurate. However, readers should confirm all dosage schedules against the manufacturer’s package information data. The Publisher, Editorial Board, and their employees accept no liability whatsoever for the consequences of any inaccurate or misleading data, opinion, or statement.